More COVID-19 Headwinds In 2021 For GlaxoSmithKline

Company Sacrificing Profits To Invest In R&D

 
• By Andrew McConaghie

The UK-headquartered company is in transition, investing heavily in biopharma R&D and preparing to spin out its consumer division.

GSK
GSK is aiming to have a broad portfolio of vaccine platforms to draw on for its R&D.

More from Anti-infective

More from Therapy Areas